Illumina Inc. has purchased Verinata Health Inc. for $350 million, plus up to $100 million in milestone payments.

The deal will give Illumina access to Verinata’s prenatal test, called verifi. The non-invasive prenatal test, which can detect Downs syndrome, Edwards syndrome and Patau syndrome, is for high-risk pregnancies. Illumina will also acquire Verinata’s intellectual property portfolio. 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.